EUR 1.02
(5.7%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 21.29 Million USD | 43.69% |
2022 | 14.81 Million USD | 18.18% |
2021 | 12.53 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 16.27 Million USD | -23.59% |
2024 Q2 | 17.43 Million USD | 7.17% |
2023 Q2 | 22 Million USD | 237.04% |
2023 Q4 | 21.29 Million USD | 12.29% |
2023 FY | 21.29 Million USD | 43.69% |
2023 Q1 | 6.53 Million USD | 0.0% |
2023 Q3 | 18.96 Million USD | -13.84% |
2022 Q1 | 12.53 Million USD | 0.0% |
2022 FY | 14.81 Million USD | 18.18% |
2022 Q3 | 14.69 Million USD | 4.86% |
2022 Q2 | 14.01 Million USD | 11.77% |
2021 FY | 12.53 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
BioNTech SE | 2.76 Billion EUR | 99.229% |
CureVac N.V. | 271.53 Million EUR | 92.159% |
Biotest Aktiengesellschaft | 945.4 Million EUR | 97.748% |
Biotest Aktiengesellschaft | 945.4 Million EUR | 97.748% |
BRAIN Biotech AG | 47.92 Million EUR | 55.57% |
Formycon AG | 387.61 Million EUR | 94.507% |
Heidelberg Pharma AG | 21.01 Million EUR | -1.327% |
Medigene AG | 10.65 Million EUR | -99.925% |